Rechargeable Implantable Thin-Film Lithium Battery

可充电植入式薄膜锂电池

• 批准号: 7325861
• 负责人: Simon K Nieh
• 金额: $ 19.38万
• 依托单位: FRONT EDGE TECHNOLOGY, INC.
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-07-13 至 2008-07-12
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7325861
• 关键词: Abdominal Cavity; Adoption; American; Ants; Artificial cardiac pacemaker; Bathing; Caliber; Carbon; Cathodes; Cells; Cellular Phone; Cephalic; Ceramics; Characteristics; Charge; Clinical; Cochlear Implants; Condition; Consensus; Cosmetics; Coupling; Daily; Data; Defibrillators; Dependence; Deposition; Development; Devices; Disadvantaged; Doctor of Medicine; Dose; Ear; Electrolytes; Electromagnetic Energy; Electromagnetics; Electronics; Epilepsy; Extravasation; Film; Goals; Government; Head; Hearing Aids; Heating; Hour; Housing; Image; Implant; Individual; Industry; Infection; Intellectual Property; Iodine; Ions; Legal patent; Letters; Licensing; Life; Light; Link; Liquid substance; Literature; Lithium; Maintenance; Manufacturer Name; Marketing; Measures; Medical; Metals; Nose; Obesity; Obsessive-Compulsive Disorder; Operative Surgical Procedures; Pacemakers; Pain; Parkinson Disease; Patients; Performance; Persons; Pharmaceutical Preparations; Pharyngeal structure; Phase; Positioning Attribute; Power Sources; Process; Prosthesis; Pump; Purpose; Quality of life; Range; Research; Risk; Safety; Sales; Side; Site; Skin; Societies; Solid; Speech; Sports; Swimming; System; Techniques; Technology; Testing; Therapeutic; Thesauri; Thick; Time; Today; Tremor; Universities; Work; chronic depression; chronic pain; commercial application; compliance behavior; cost; day; design; electric impedance; energy density; evaluation/testing; implantable device; improved; manufacturing process; neurosurgery; new technology; particle; professor; programs; seal; size; solid state; vapor

DESCRIPTION (provided by applicant): Battery-powered implantable systems are now being used in a wide array of therapeutic and prosthetic applications such as cardiac pacemakers/defibrillators, drug pumps, and more recently, neurostimulators for Parkinson's, pain relief, and cochlear implants. For most of these applications, the energy-density and life of currently-available batteries is insufficient to enable fully-implantable systems, and the battery power supply must remain external. In Phase I of the proposed program, we intend to demonstrate that a new battery technology, thin-film rechargeable lithium, will enable fully-implantable systems, by demonstrating the feasibility for one particular application: a cochlear implant. This will require that we demonstrate the feasibility of achieving an energy-density of 500mWh/cc (3X to 4X current implantable rechargeable batteries), a 20-year life (5X to 10X current batteries), a 5- or 10-minute recharge capability (not available in current batteries), and improved safety (by using all solid-state battery materials, thereby eliminating the toxic liquid electrolyte in current batteries). In Phase I, we will fabricate individual battery cells and conduct tests to demonstrate these performance capabilities. In Phase II, we will complete the battery by stacking cells within a hermetically- sealed case, and produce a sufficient quantity of batteries for extensive in-house testing and evaluation by a major cochlear-implant manufacturer. Proposed Commercial Applications: Our initial battery will be designed for cochlear implants, which have current annual sales of approximately $ 425 million and expected to grow by approximately 20% annually. Upon completion of the cochlear demonstration battery, we will pursue the other implantable neuromodulation applications, which have current annual sales of $1.6 billion and expected to grow to $10 billion in 10 to 15 years. In addition to neuromodulation applications, our battery technology will be suitable for rechargeable batteries for hearing aids, currently estimated to be a $5 billion dollar industry. Thesaurus Terms: Implantable medical power source, thin-film battery, lithium battery, cochlear implant, neurostimulator power source, neuromodulation implant battery, hearing aid battery. Implantable battery-powered systems are increasingly being used for treating a wide array of neuromodulation applications including cochlear implants, neurostimulation for treating Parkinson's disease, tremors, epilepsy, chronic depression, chronic pain, obesity, angina, obsessive-compulsive disorder, and implantable drug pumps which deliver small precisely controlled doses of drugs directly to targeted sites in the body. For many applications, the energy-density and life of currently-available batteries is inadequate to enable fully-implantable neuromodulation systems. NanoEnergy(r), Front Edge Technology's (FET) novel, rechargeable, thin-film, lithium battery is enabling technology for the successful introduction of fully implantable neuromodulation devices.

描述（由申请人提供）：现在使用电池供电的可植入系统用于多种治疗和假体应用中，例如心脏起搏器/除颤器，药物泵，以及最近的帕金森氏症神经仿真器，疼痛缓解和同情植入物。对于大多数这些应用，当前可用的电池的能量密度和寿命不足以实现完全不可植入的系统，并且电池电源必须保持外部。在拟议程序的第一阶段中，我们打算证明，一种新的电池技术，即薄膜可充电锂，可以通过证明一种特定应用的可行性来实现完全植入的系统：一种人工耳蜗。这将需要我们证明实现500mWh/cc（3倍至4倍的能量密度（3倍至4倍）的可行性，可充电电池），20年的寿命（5倍至10倍电池），5或10分钟的充电功能（在电流电池中不可用），并使用当前的固定电池材料，使用固体电池，并使用固体电池材料，用于使用固体电池，并使用所有固体电池材料。在第一阶段，我们将制造单个电池电池并进行测试以证明这些性能能力。在第二阶段，我们将通过将电池堆叠在密封的情况下来完成电池，并生产出足够数量的电池，用于由主要的人工耳蜗制造商进行广泛的内部测试和评估。拟议的商业应用程序：我们的初始电池将用于人工耳蜗，目前的年销售额约为4.25亿美元，预计每年增长约20％。人工耳蜗示范电池完成后，我们将追求其他可植入的神经调节申请，目前的年销售额为16亿美元，预计将在10至15年内增长到100亿美元。除了神经调节应用外，我们的电池技术还适用于可充电助听器的电池，目前估计为50亿美元的行业。词库术语：可植入的医疗电源，薄膜电池，锂电池，人工耳蜗，神经刺激器电源，神经调节植入物电池，助听器电池。越来越多地使用植入电池供电的系统来治疗广泛的神经调节应用，包括人工耳蜗植入物，治疗帕金森氏病的神经刺激，震颤，癫痫，慢性抑郁，慢性疼痛，慢性疼痛，肥胖，肥胖，心绞痛，强迫症，强迫症和可植入的药物泵的定位剂量较小的药物，以供应剂量精确地剂量。对于许多应用，当前可用的电池的能量密度和寿命不足以实现完全可植入的神经调节系统。纳米生物（R），前边缘技术的（FET）小说，可充电，薄膜，锂电池正在为成功引入完全可植入的神经调节设备提供技术。